"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
Descriptor ID |
D011720
|
MeSH Number(s) |
D03.383.129.539
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 0 | 1 | 1 |
2000 | 3 | 3 | 6 |
2001 | 1 | 2 | 3 |
2002 | 1 | 4 | 5 |
2003 | 0 | 4 | 4 |
2004 | 3 | 11 | 14 |
2005 | 6 | 3 | 9 |
2006 | 6 | 6 | 12 |
2007 | 7 | 4 | 11 |
2008 | 13 | 5 | 18 |
2009 | 11 | 6 | 17 |
2010 | 14 | 4 | 18 |
2011 | 14 | 5 | 19 |
2012 | 20 | 16 | 36 |
2013 | 26 | 11 | 37 |
2014 | 25 | 9 | 34 |
2015 | 38 | 18 | 56 |
2016 | 31 | 19 | 50 |
2017 | 34 | 17 | 51 |
2018 | 50 | 20 | 70 |
2019 | 29 | 27 | 56 |
2020 | 20 | 19 | 39 |
2021 | 24 | 21 | 45 |
2022 | 3 | 30 | 33 |
2023 | 2 | 12 | 14 |
2024 | 7 | 2 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 Apr 09; 8(7):1639-1650.
-
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 Mar 26; 8(6):1515-1528.
-
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569.
-
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica. 2024 Feb 01; 109(2):676-681.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.